spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  intratumoral 

 HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2022
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
Devices Oncology
 HSMN NewsFeed - 10 Jan 2022
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT(TM) in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events
Devices Oncology
 HSMN NewsFeed - 3 Jan 2022
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
Devices Oncology
 HSMN NewsFeed - 17 Dec 2021
OncoSec Announces Changes to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
Devices Oncology FDA
 HSMN NewsFeed - 14 Apr 2021
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse(TM)" for the Treatment of Solid Tumors
Devices Oncology Regulatory
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Feb 2021
OncoSec Strengthens Management Team With Two New Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Dec 2020
ImmVira Announces Series C Financing with Leading Specialist Investors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2020
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Devices Oncology Venture Capital
 HSMN NewsFeed - 22 Jan 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jan 2020
Presage Receives FDA Clearance of First IND Application for Trial to Evaluate Investigational Oncology Agents with CIVO(TM) Technology
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 10 Apr 2019
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Feb 2019
Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Dec 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Nov 2018
RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2018
OncoSec Appoints Robert Ward to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Oct 2017
OncoSec Presents Positive Phase 2 Data for ImmunoPulse(R) IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Aug 2016
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2016
OncoSec Announces $10 Million At-The-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2012
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
MagForce signs distribution agreement with leading Russian medical device distribution company DELRUS
Devices Oncology Distribution
 HSMN NewsFeed - 26 Mar 2012
MagForce AG Announces Company Restructuring and Revised Corporate Strategy for 2012
Devices
 HSMN NewsFeed - 10 Oct 2011
MagForce AG Announces Treatment of Recurrent Glioblastoma Patient with NanoTherm(R) Therapy
Devices Oncology
 HSMN NewsFeed - 1 Nov 2010
BSD Medical Reports Receipt of CE Mark Approval for MicroThermX Microwave Ablation System
Devices Oncology Regulatory
 HSMN NewsFeed - 18 Aug 2010
BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System
Devices Oncology FDA
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jun 2007
Inovio Biomedical's Selective Electrochemical Tumor Ablation Therapy Shows Safety, Tolerability, and Significant Complete Responses in Breast Cancer Study
Devices Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Inovio Biomedical Stops Enrollment of Phase III Clinical Trials for Head & Neck Cancer
Devices Drug Delivery Oncology
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2007
Encore Therapeutics Inc. Reports Efficacy Data on a Long-Acting Local Anesthetic Drug
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Mayo Clinic Develops Medical Device That Reduces the Need for Invasive Surgical Biopsy Procedures
Devices
 HSMN NewsFeed - 14 Nov 2006
Inovio Biomedical Grants VGX Pharmaceuticals License to Develop Novel Cancer Therapeutic
Biopharmaceuticals Oncology Drug Delivery Licensing
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Oct 2006
RITA Medical Highlights Recent Clinical Publications Discussing Local Therapy Devices in the Treatment of Liver Tumors Associated With Colorectal Cancer
Devices Oncology
 HSMN NewsFeed - 23 May 2006
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 24

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 24 additional stories matching:
intratumoral
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.